UBS Group Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Neutral

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by UBS Group from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Thursday,Briefing.com Automated Import reports. They presently have a $738.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $1,130.00. UBS Group’s target price points to a potential upside of 4.91% from the stock’s previous close.

A number of other brokerages have also issued reports on REGN. Oppenheimer dropped their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Bank of America restated an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price on the stock. Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $703.43 on Thursday. Regeneron Pharmaceuticals has a 12-month low of $666.25 and a 12-month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market capitalization of $77.30 billion, a price-to-earnings ratio of 17.41, a price-to-earnings-growth ratio of 1.60 and a beta of 0.10. The firm’s fifty day moving average price is $746.43 and its 200 day moving average price is $956.18.

Institutional Trading of Regeneron Pharmaceuticals

A number of large investors have recently modified their holdings of REGN. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. Fairfield Financial Advisors LTD acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $37,000. Truvestments Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $39,000. Finally, Itau Unibanco Holding S.A. bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $42,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.